Irisinemia: A novel concept to coin in clinical medicine?

Annals of Nutrition and Metabolism

Volumn 63, Issue 1-2, 2013, Pages 60-61

  Sanchis Gomar, Fabian ^a   Perez Quilis, Carme ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR 21; FOLLISTATIN LIKE 1 PROTEIN; FOLLISTATIN RELATED PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; IRISIN; KERATINOCYTE DERIVED CHEMOKINE; LEUKEMIA INHIBITORY FACTOR; LIVER ENZYME; MYOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADIPOCYTOKINE; MESSENGER RNA; PEPTIDE; TRIACYLGLYCEROL;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; BODY MASS; BROWN ADIPOSE TISSUE; CHRONIC KIDNEY DISEASE; CLINICAL MEDICINE; CYTOKINE RELEASE; ELISA KIT; ENERGY EXPENDITURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; IRISINEMIA; LIPID LIVER LEVEL; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE; BODY WEIGHT; BROWN ADIPOCYTE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; ENDURANCE TRAINING; FNDC5 GENE; GENE; GENE INDUCTION; GENE OVEREXPRESSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFE EXPECTANCY; METABOLIC SYNDROME X; NONHUMAN; PROTEIN EXPRESSION; SARCOPENIA; STANDARDIZATION; TRANSCRIPTION INITIATION;

BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, TYPE 2; FIBRONECTINS; HUMANS; METABOLIC DISEASES; MUSCLE, SKELETAL; OBESITY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885582189     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000354090     Document Type: Review

References (16)

1. Febbraio MA, Pedersen BK: Contraction-induced myokine production and release: Is skeletal muscle an endocrine organ Exerc Sport Sci Rev 2005; 33: 114-119
2. Duzova H: Skeletal muscle, myokines and health. Med Sci 2012; 1: 211-231
3. Sanchis-Gomar F: The skeletal muscle-metabolism axis in prostate cancer therapy. N Engl J Med 2013; 367: 2257-2258
4. Booth FW, Roberts CK, Laye MJ: Lack of exercise is a major cause of chronic diseases. Compr Physiol 2012; 2: 1143-1211
5. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM: A PCG1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
6. Polyzos SA, Kountouras J, Shields K, Mantzoros CS: Irisin: A renaissance in metabolism Metabolism 2013, E-pub ahead of print
7. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Crujeiras AB, Seoane LM, Casanueva FF, Pardo M: FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013; 8:e60563
8. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG: Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
9. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Manuel-Fernandez-Real J: Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98:E769-E778
10. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC: Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365-369
11. Wen MS, Wang CY, Lin SL, Hung KC: Decrease in irisin in patients with chronic kidney disease. PLoS One 2013; 8:e64025
12. Staiger H, Bohm A, Scheler M, Berti L, Machann J, Schick F, Machicao F, Fritsche A, Stefan N, Weigert C, Krook A, Haring HU, de Angelis MH: Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived ?browning? factor irisin, determines insulin sensitivity. PLoS One 2013; 8:e61903
13. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, Han CK, Zhuang XJ, Lu Y, Li XJ, Yang SY, Li XY: Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013, E-pub ahead of print
14. Spiegelman BM: Banting Lecture 2012: Regulation of adipogenesis-toward new therapeutics for metabolic disease. Diabetes 2013; 62: 1774-1782
15. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL: Irisin: A new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes 2012; 4: 196
16. Hojlund K, Bostrom P: Irisin in obesity and type 2 diabetes. J Diabetes Complications 2013; 27: 303-304